NKMAX Completes First Dosing in Alzheimer's Clinical Trial

[Asia Economy Reporter Hyunseok Yoo] NKMAX announced on the 1st that it has successfully completed the first injection of three clinical Alzheimer’s patients.

This clinical trial has been underway since receiving IND approval in August last year. After completing Phase 1 clinical trials in Mexico, the trial will be expanded to multinational clinical trials including the United States.

The clinical trial involves a total of 21 patients. ▲Cohorts 1 to 3 consist of 9 patients in total (3 patients per cohort), who will be administered SNK01 at doses of 1 billion, 2 billion, and 4 billion cells respectively, four times at three-week intervals to determine the Maximum Tolerated Dose (MTD). Subsequently, ▲Cohort 4, consisting of 12 patients, will be evaluated for the safety, tolerability, and exploratory efficacy of SNK01 at the MTD.

The three patients who completed the first injection belong to Cohort 1 and received 1 billion cells of SNK01.

Park Sang-woo, CEO of NKMAX, stated, “NKMAX is conducting the clinical trial as planned and aims to complete it within this year. This year, we will deliver good results not only in oncology but also in Alzheimer’s clinical trials.” He added, “Until last year, we were in an expansion phase discussing collaborations with global pharmaceutical companies while conducting clinical trials, but from 2021 onward, it will be a harvest season where business outcomes will materialize.” He continued, “The allogeneic (SNK02) clinical trial is also scheduled to start in the first half of the year, and we expect to share news of contracts with global pharmaceutical companies.”

This content was produced with the assistance of AI translation services.